Spectral flow cytometry has revolutionized traditional single-cell profiling to a new era of high-dimensional analysis, allowing for unprecedented deep phenotyping and more precise cell characterization, thereby significantly enhancing our multiplexing capability. The recent application of this technology in clinical settings has been redefining the landscape of clinical diagnostic panels and immune monitoring, particularly for hematologic malignancies, immunological disorders, and drug discovery. Emerging technologies like ghost cytometry, LASE, and imaging flow cytometry are advancing cytometry by improving sensitivity, throughput, and spatial resolution. In this review, we discuss the requirements, challenges, and considerations for spectral applications in clinical diagnostic laboratories and pharmaceutical/contract research organization (CRO) settings. We discuss how these recent innovations are set to push the boundaries of diagnostic accuracy and analytical power, heralding a new frontier in clinical cytometry with the potential to dramatically enhance patient care and treatment outcomes.
Keywords: biomarkers; clinical flow cytometry; clinical trials; data standardization; diagnostic flow cytometry; high-dimensional analysis; high-dimensional cytometry; immune monitoring; immune profiling; spectral flow cytometry.